206 related articles for article (PubMed ID: 28593463)
1. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.
Atlan P; Bayar MA; Lanoy E; Besse B; Planchard D; Ramon J; Raynard B; Antoun S
Support Care Cancer; 2017 Nov; 25(11):3365-3373. PubMed ID: 28593463
[TBL] [Abstract][Full Text] [Related]
2. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
[TBL] [Abstract][Full Text] [Related]
3. Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.
Antoun S; Morel H; Souquet PJ; Surmont V; Planchard D; Bonnetain F; Foucher P; Egenod T; Krakowski I; Gaudin H; Debieuvre D
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):782-793. PubMed ID: 30932365
[TBL] [Abstract][Full Text] [Related]
4. Sarcopenic obesity by the ESPEN/EASO criteria for predicting mortality in advanced non-small cell lung cancer.
Zhou J; Luo L; Xie L; Hu S; Tan L; Lei X; Luo X; Yang M
Clin Nutr; 2023 Jun; 42(6):817-824. PubMed ID: 37084468
[TBL] [Abstract][Full Text] [Related]
5. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.
Cortellini A; Palumbo P; Porzio G; Verna L; Giordano AV; Masciocchi C; Parisi A; Cannita K; Ficorella C; Bozzetti F
Thorac Cancer; 2018 Dec; 9(12):1623-1630. PubMed ID: 30259689
[TBL] [Abstract][Full Text] [Related]
6. Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer.
Matsuo Y; Mitsuyoshi T; Shintani T; Iizuka Y; Mizowaki T
J Geriatr Oncol; 2018 Nov; 9(6):589-593. PubMed ID: 29779799
[TBL] [Abstract][Full Text] [Related]
7. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
Antoun S; Bayar MA; Dyevre V; Lanoy E; Smolenschi C; Ducreux M
BMC Cancer; 2019 Aug; 19(1):847. PubMed ID: 31462288
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer.
Kimura M; Naito T; Kenmotsu H; Taira T; Wakuda K; Oyakawa T; Hisamatsu Y; Tokito T; Imai H; Akamatsu H; Ono A; Kaira K; Murakami H; Endo M; Mori K; Takahashi T; Yamamoto N
Support Care Cancer; 2015 Jun; 23(6):1699-708. PubMed ID: 25430482
[TBL] [Abstract][Full Text] [Related]
9. Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).
Recio-Boiles A; Galeas JN; Goldwasser B; Sanchez K; Man LMW; Gentzler RD; Gildersleeve J; Hollen PJ; Gralla RJ
Support Care Cancer; 2018 Jul; 26(7):2353-2359. PubMed ID: 29417293
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
11. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis.
Baracos VE; Reiman T; Mourtzakis M; Gioulbasanis I; Antoun S
Am J Clin Nutr; 2010 Apr; 91(4):1133S-1137S. PubMed ID: 20164322
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C
Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905
[TBL] [Abstract][Full Text] [Related]
13. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab.
Degens JHRJ; Dingemans AC; Willemsen ACH; Gietema HA; Hurkmans DP; Aerts JG; Hendriks LEL; Schols AMWJ
J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):657-664. PubMed ID: 33951326
[TBL] [Abstract][Full Text] [Related]
15. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival.
Kiss N; Beraldo J; Everitt S
Support Care Cancer; 2019 Jul; 27(7):2657-2664. PubMed ID: 30478673
[TBL] [Abstract][Full Text] [Related]
16. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
[TBL] [Abstract][Full Text] [Related]
17. Muscle mass and association to quality of life in non-small cell lung cancer patients.
Bye A; Sjøblom B; Wentzel-Larsen T; Grønberg BH; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Jordhøy M
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):759-767. PubMed ID: 28493418
[TBL] [Abstract][Full Text] [Related]
18. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.
Grønberg BH; Valan CD; Halvorsen T; Sjøblom B; Jordhøy MS
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1347-1355. PubMed ID: 31385663
[TBL] [Abstract][Full Text] [Related]
19. Exploring the dietary protein intake and skeletal muscle during first-line anti-neoplastic treatment in patients with non-small cell lung cancer.
Tobberup R; Rasmussen HH; Holst M; Jensen NA; Falkmer UG; Bøgsted M; Delekta AM; Carus A
Clin Nutr ESPEN; 2019 Dec; 34():94-100. PubMed ID: 31677719
[TBL] [Abstract][Full Text] [Related]
20. Skeletal muscle mass and adipose tissue alteration in critically ill patients.
Dusseaux MM; Antoun S; Grigioni S; Béduneau G; Carpentier D; Girault C; Grange S; Tamion F
PLoS One; 2019; 14(6):e0216991. PubMed ID: 31194755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
